Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04177706 · ClinicalTrials.gov registry record · Phase 2
Ketamine for the Treatment of Opioid Use Disorder and Depression
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT04177706 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 21 participants.
The verdict
NCT04177706, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Interventions
- DRUG Placebo
- DRUG Ketamine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-12-17 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04177706
The ClinicalTrials.gov registry entry for NCT04177706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04177706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04177706 about?
NCT04177706 is a clinical study titled "Ketamine for the Treatment of Opioid Use Disorder and Depression". The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. ...
What is the current status of trial NCT04177706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2020-12-17. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT04177706?
The interventions under investigation include: Placebo (DRUG), Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04177706?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.